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INTRODUCTION: Novel coronavirus disease 2019 
(COVID-19) associated severe hypoxemic respiratory failure is mediated by severe inflammation that 
may be mitigated by administration of corticosteroids. Our aim was to evaluate pattern and effects of 
corticosteroid use in these patients during an initial surge of the pandemic. 
METHODS: An observational study of COVID-19 patients between March 1 and April 27, 2020 was 
conducted  
at a tertiary care academic hospital in Indianapolis, IN. Comparison of patients who received 
corticosteroids plus standard care to standard care only was done. Corticosteroid type, dose and timing 
of administration were analyzed. Outcome measures included number of patients requiring intubation, 
duration of mechanical ventilation, length of ICU stay and inpatient mortality. Descriptive statistics 
outlined the type, timing and duration of administration of corticosteroids during severe COVID-19. 
Clinical course and laboratory metrics were compared between patient cohorts. 
RESULTS: 626 patients tested positive for severe respiratory syndrome coronavirus-2 RNA by PCR during 
the specified time period. 136 COVID-19 patients admitted to the ICU were included in the analysis, and 
72 (53%) received corticosteroids. Groups had similar demographics: age (60.5 vs. 65; p=0.083), sex 
(47% male vs. 39% female; p=0.338) and comorbidities. Corticosteroid group had increased severity of 
illness: PaO2/FiO2 ratios (113 vs. 130; p=0 .014) and SOFA scores (8 vs. 5.5; p<0.001). There was no 
difference in overall mortality (21% vs. 30%; p=0.234) or proportion of patients intubated (78 vs. 64%; 
p=0.078). There was no mortality difference among intubated patients (27% vs. 15%; p=0.151) however, 
there were no deaths among patients who were not intubated and received corticosteroids (0% vs 57%; 
p <0.001). Administering corticosteroids early (within 48 hours vs. 2-7 days, vs >7 days) was associated 
with decrease in proportion of patients intubated (66% vs. 87% vs. 100%; p=0.045), ICU days (6 vs. 16 vs. 
18; p<0.001), and ventilator days (3 vs. 12 vs. 14; p<0.001). Methylprednisolone was used in 45% of 
patients. 
CONCLUSIONS: Early administration of corticosteroids in hypoxemic respiratory failure of COVID-19 
improves survival in non-intubated patients, decreases ICU stay and may prevent intubation. 
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